

S.N	Author	Publication	Importance	Clinical relevance
1	Corresponding	Gupta A, Gogia A , Deo S, Sharma DN, Mathur S, Sagiraju HKR. Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer. Cancer Treat Res Commun. 2023 Jul 9;36:100741.	First study from India : demonstrated impact of neo adjuvant chemotherapy (2 different regimen) and targeted therapy in HER2 neu positive breast cancer	Non anthracycline based regimen is equally effective in Indian breast cancer patients
2	First	Gogia A , Deo SVS, Sharma D, Phulia RK, Thulkar S, Malik PS, Mathur S. Discordance in Biomarker Expression in Breast Cancer After Metastasis: Single Center Experience in India. J Glob Oncol. 2019 Apr;5:1-8. doi: 10.1200/JGO.18.00184.	First study from India : Discordance of receptor status at the time of relapse (different from the western population)	Repeat biopsy has to be done at the time of relapse in breast cancer
3	First	Gogia A , Deo SVS, Sharma D, Thulkar S, Kumar R, Malik PS, Mathur S. Clinicopathologic Characteristics and Treatment Outcomes of Patients With Up-Front Metastatic Breast Cancer: Single-Center Experience in India. J Glob Oncol. 2019 Mar;5:1-9. doi: 10.1200/JGO.18.00265	First study from India: Treatment outcome in metastatic breast cancer	Importance of targeted therapy in metastatic breast cancer
4	First	Gogia A , S Deo SV, Sharma DN, Mathur S. Oligometastatic breast cancer: An institutional analysis. Indian J Cancer. 2022 Apr-Jun;59(2):257-262.	First study from India on oligometastatic breast cancer	Outcome of oligometastatic breast cancer is same as locally advanced breast cancer
5	First	Gogia A , Nair S, Arora S, Kumar L, Sharma A, Gupta R, Biswas A, Mallick S. Impact of Cell-of-Origin on Outcome of Patients with Diffuse Large B-Cell Lymphoma Treated with Uniform R-CHOP Protocol: A Single-Center Retrospective Analysis from North India. Front Oncol. 2021 Dec 2;11:770747	First study from India to demonstrate the outcome of non Hodgkin lymphoma with uniform protocol	No rationale for doing Hans algorithm in the management of DLBCL
6	First	Gogia A , Raina V, Deo SV, Shukla NK, Mohanti BK Male breast cancer: A single institute experience. Indian J Cancer. 2015 Oct-Dec;52(4):526-9	First study of Indian male breast cancer patients	Evaluate Prognostic factor and outcome
7	First	Gogia A , Raina V, Deo SVS, Shukla NK, Mathur S, Mohanti BK, Sharma DN. Clinicopathological characteristics and treatment outcome in invasive lobular carcinoma of the breast: An Indian experience. Indian J Cancer. 2018 Oct-Dec;55(4):344-347. doi: 10.4103/ijc.IJC_428_18.	First study of Invasive lobular carcinoma from India	Evaluate Prognostic factor and outcome in invasive lobular cancer

8	First	Gogia A , Deo SV, Shukla NK, Mohanti BK, Raina V. Pregnancy associated breast cancer: an institutional experience. Indian J Cancer . 2014 Apr-Jun;51(2):167-9.	First study of pregnancy associated breast cancer from India	Evaluate Prognostic factor and outcome in pregnancy associated breast cancer
9	Corresponding	Arora S, Gogia A , Deo S, Sharma D, Mathur SR. Neoadjuvant pertuzumab plus trastuzumab in combination with anthracycline-free chemotherapy regimen in patients with HER2 positive breast cancer-Real-world data from a single center in India. Cancer Treat Res Commun . 2021;29:100483. doi: 10.1016/j.ctarc.2021.100483.	First study of dual targeted therapy from India	Dual targeted therapy have impact on pathological complete response and treatment outcome
10	First	Gogia A , Sharma A, Raina V, Kumar L, Vishnubhatla S, Gupta R, Kumar R. Assessment of 285 cases of chronic lymphocytic leukemia seen at single large tertiary center in Northern India. Leuk Lymphoma . 2012 Oct;53(10):1961-5	The Largest study from Asia on Chronic Lymphocytic leukemia patients	Evaluate Prognostic factor and outcome in Chronic Lymphocytic leukemia